12-year-old Alexis Bortell, who suffers from childhood epilepsy, just served U.S. Attorney General Jeff Sessions with a lawsuit.
Bortell is suing Sessions over what the lawsuit claims is an unconstitutional federal prohibition on medical marijuana, according to The Hill.
The Colorado native, who depends on a strain of cannabis oil to keep her seizures under control, told Denver's Fox 31 that she hopes the lawsuit will at least normalize medical marijuana. Her best hope, she said, is that it will legalize it nationwide.
Marijuana currently sits in the most restrictive category according to the Controlled Substance Act - Schedule I. This places marijuana in the same boat as heroin, which significantly limits the amount of medical cannabis research that can be conducted.
Cocaine and methamphetamine are placed in the less-restrictive Schedule II category.
Unfortunately for Sessions, this lawsuit is just the latest in a series of efforts to convince the (U.S.) Department of Justice to reclassify the drug to a different tier.
In fact, California lawmakers recently voted on a joint resolution urging the federal government to reclassify marijuana immediately.
Reclassifying marijuana would make it easier for researchers to work with the plant, which could result in the discovery of more life-saving drugs like the one that Bortell (and thousands of other children) rely on.
There's no doubt marijuana reclassification would be a huge boon for the industry.
However, we've got our eye on one company that is leading the medical marijuana space right now - regardless of what category marijuana sits in.
And for this company, the public and litigious pressure on Jeff Sessions can only be a good thing. Plus, it's due for another round of 1,000%-plus gains in the coming months...
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
Our Favorite Medical Marijuana Stock Now
We're talking about GW Pharmaceuticals Inc. (NYSE: GWPH).
Cash Windfall: Marijuana stocks are seeing triple-digit gains of 224%... 378%... even an exceptional 751%. Learn how to start investing in marijuana with this "pot investment" plan. Read more...
GW Pharma has been cultivating strains of the marijuana plant with an eye to increasing concentrations of two key ingredients with major healing properties: CBD and THC.
And it's way ahead of its competitors.
"Its research has been fruitful, showing incredible promise," says Money Morning Director of Technology and Venture Capital Research - and renowned pot stock expert - Michael Robinson.
In fact, he sees opportunities to realize 1,000% gains from this company alone.
After all, its newest drug is about to dramatically change the lives of the 3 million epilepsy sufferers in the United States - just like Bortell. The drug is called Epidiolex, and it has been quickly moving through clinical trials.
"In fact, Epidiolex's U.S. trials are already wrapped up, and GW plans to file for U.S. Food and Drug Administration approval soon," said Michael.
Epidiolex could be on the market just months after filing for FDA approval. Following approval, GW Pharma will have exclusive sales rights to the drug for seven years in the United States and 10 years in Europe.
"Those will be very profitable years," said Michael. "Simply put, sales for juveniles alone could be a blockbuster drug launch. Solely based on approval for children with epilepsy, annual sales for Epidiolex may exceed $1 billion five years from now - 'official' blockbuster status."
If you're still in doubt about the demand for cannabis-based epilepsy treatment, just remember: Children are literally suing for it.
"Once the medical community sees how compounds such as CBD, CBDV, and THC deliver much better results than existing treatments, GW Pharma and other cannabis-focused stocks will be no longer be seen as outliers; they'll be must-own stocks and essential earners in savvy investors' portfolios," Michael added.
That means now is the time to get in on this revolutionary company.
Here's how you can do it - plus, how to cash in on 30 of the best pot stocks today...
Pave Your Way to Future Wealth by Investing in the Best Pot Stocks Today
GW Pharma was a fixture in Michael's 2016 Roadmap to Marijuana Millions legal cannabis portfolio.
Those who got their copy of Roadmap and got in early have already seen peak gains of more than 65% from GW, in addition to 10 double-digit winners and eight triple-digit winners from other marijuana stock recommendations.
Michael's last round of marijuana stock trades was so successful, he couldn't pass up doing it again.
So, for the last eight months, Michael and his team have dedicated thousands of man hours and over $250,000 toward the most exhaustive analysis of the marijuana industry to date.
He's met with leading growers, dispensaries, angel investors...
And he's vetted the next generations of weed stocks that are poised to make marijuana investors rich.
They're all in his newly released and updated Roadmap to Marijuana Millions: Phase II. This book contains an incredibly diversified list of more than 30 of the best legal marijuana stocks on the market - including details on five tiny weed stocks that could potentially turn a small stake into $100,000.
Don't wait - this market could be worth $20 billion or more by 2020, and this "weed investors' bible" can show you how to get the best possible shot at your share of the profits.
Click here to learn how to get your copy today...
Follow Money Morning on Twitter @moneymorning, Facebook, and LinkedIn.